Costs and financial feasibility of malaria elimination

Oliver Sabot, Justin M. Cohen, Michelle S. Hsiang, James G. Kahn, Suprotik Basu, Linhua Tang, Bin Zheng, Qi Gao, Linda Zou, Allison Tatarsky, Shahina Aboobakar, Jennifer Usas, Scott Barrett, Jessica L. Cohen, Dean T. Jamison, Richard G A Feachem

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The marginal costs and benefits of converting malaria programmes from a control to an elimination goal are central to strategic decisions, but empirical evidence is scarce. We present a conceptual framework to assess the economics of elimination and analyse a central component of that framework - potential short-term to medium-term financial savings. After a review that showed a dearth of existing evidence, the net present value of elimination in five sites was calculated and compared with effective control. The probability that elimination would be cost-saving over 50 years ranged from 0 to 42, with only one site achieving cost-savings in the base case. These findings show that financial savings should not be a primary rationale for elimination, but that elimination might still be a worthy investment if total benefits are sufficient to outweigh marginal costs. Robust research into these elimination benefits is urgently needed.

Original languageEnglish (US)
Pages (from-to)1604-1615
Number of pages12
JournalThe Lancet
Volume376
Issue number9752
DOIs
StatePublished - Nov 6 2010

Fingerprint

Malaria
Costs and Cost Analysis
Cost Savings
Cost-Benefit Analysis
Economics
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sabot, O., Cohen, J. M., Hsiang, M. S., Kahn, J. G., Basu, S., Tang, L., ... Feachem, R. G. A. (2010). Costs and financial feasibility of malaria elimination. The Lancet, 376(9752), 1604-1615. https://doi.org/10.1016/S0140-6736(10)61355-4

Costs and financial feasibility of malaria elimination. / Sabot, Oliver; Cohen, Justin M.; Hsiang, Michelle S.; Kahn, James G.; Basu, Suprotik; Tang, Linhua; Zheng, Bin; Gao, Qi; Zou, Linda; Tatarsky, Allison; Aboobakar, Shahina; Usas, Jennifer; Barrett, Scott; Cohen, Jessica L.; Jamison, Dean T.; Feachem, Richard G A.

In: The Lancet, Vol. 376, No. 9752, 06.11.2010, p. 1604-1615.

Research output: Contribution to journalArticle

Sabot, O, Cohen, JM, Hsiang, MS, Kahn, JG, Basu, S, Tang, L, Zheng, B, Gao, Q, Zou, L, Tatarsky, A, Aboobakar, S, Usas, J, Barrett, S, Cohen, JL, Jamison, DT & Feachem, RGA 2010, 'Costs and financial feasibility of malaria elimination', The Lancet, vol. 376, no. 9752, pp. 1604-1615. https://doi.org/10.1016/S0140-6736(10)61355-4
Sabot O, Cohen JM, Hsiang MS, Kahn JG, Basu S, Tang L et al. Costs and financial feasibility of malaria elimination. The Lancet. 2010 Nov 6;376(9752):1604-1615. https://doi.org/10.1016/S0140-6736(10)61355-4
Sabot, Oliver ; Cohen, Justin M. ; Hsiang, Michelle S. ; Kahn, James G. ; Basu, Suprotik ; Tang, Linhua ; Zheng, Bin ; Gao, Qi ; Zou, Linda ; Tatarsky, Allison ; Aboobakar, Shahina ; Usas, Jennifer ; Barrett, Scott ; Cohen, Jessica L. ; Jamison, Dean T. ; Feachem, Richard G A. / Costs and financial feasibility of malaria elimination. In: The Lancet. 2010 ; Vol. 376, No. 9752. pp. 1604-1615.
@article{a4f513be9e4244d89f45e388ef44ffdc,
title = "Costs and financial feasibility of malaria elimination",
abstract = "The marginal costs and benefits of converting malaria programmes from a control to an elimination goal are central to strategic decisions, but empirical evidence is scarce. We present a conceptual framework to assess the economics of elimination and analyse a central component of that framework - potential short-term to medium-term financial savings. After a review that showed a dearth of existing evidence, the net present value of elimination in five sites was calculated and compared with effective control. The probability that elimination would be cost-saving over 50 years ranged from 0 to 42, with only one site achieving cost-savings in the base case. These findings show that financial savings should not be a primary rationale for elimination, but that elimination might still be a worthy investment if total benefits are sufficient to outweigh marginal costs. Robust research into these elimination benefits is urgently needed.",
author = "Oliver Sabot and Cohen, {Justin M.} and Hsiang, {Michelle S.} and Kahn, {James G.} and Suprotik Basu and Linhua Tang and Bin Zheng and Qi Gao and Linda Zou and Allison Tatarsky and Shahina Aboobakar and Jennifer Usas and Scott Barrett and Cohen, {Jessica L.} and Jamison, {Dean T.} and Feachem, {Richard G A}",
year = "2010",
month = "11",
day = "6",
doi = "10.1016/S0140-6736(10)61355-4",
language = "English (US)",
volume = "376",
pages = "1604--1615",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9752",

}

TY - JOUR

T1 - Costs and financial feasibility of malaria elimination

AU - Sabot, Oliver

AU - Cohen, Justin M.

AU - Hsiang, Michelle S.

AU - Kahn, James G.

AU - Basu, Suprotik

AU - Tang, Linhua

AU - Zheng, Bin

AU - Gao, Qi

AU - Zou, Linda

AU - Tatarsky, Allison

AU - Aboobakar, Shahina

AU - Usas, Jennifer

AU - Barrett, Scott

AU - Cohen, Jessica L.

AU - Jamison, Dean T.

AU - Feachem, Richard G A

PY - 2010/11/6

Y1 - 2010/11/6

N2 - The marginal costs and benefits of converting malaria programmes from a control to an elimination goal are central to strategic decisions, but empirical evidence is scarce. We present a conceptual framework to assess the economics of elimination and analyse a central component of that framework - potential short-term to medium-term financial savings. After a review that showed a dearth of existing evidence, the net present value of elimination in five sites was calculated and compared with effective control. The probability that elimination would be cost-saving over 50 years ranged from 0 to 42, with only one site achieving cost-savings in the base case. These findings show that financial savings should not be a primary rationale for elimination, but that elimination might still be a worthy investment if total benefits are sufficient to outweigh marginal costs. Robust research into these elimination benefits is urgently needed.

AB - The marginal costs and benefits of converting malaria programmes from a control to an elimination goal are central to strategic decisions, but empirical evidence is scarce. We present a conceptual framework to assess the economics of elimination and analyse a central component of that framework - potential short-term to medium-term financial savings. After a review that showed a dearth of existing evidence, the net present value of elimination in five sites was calculated and compared with effective control. The probability that elimination would be cost-saving over 50 years ranged from 0 to 42, with only one site achieving cost-savings in the base case. These findings show that financial savings should not be a primary rationale for elimination, but that elimination might still be a worthy investment if total benefits are sufficient to outweigh marginal costs. Robust research into these elimination benefits is urgently needed.

UR - http://www.scopus.com/inward/record.url?scp=78149359894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149359894&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)61355-4

DO - 10.1016/S0140-6736(10)61355-4

M3 - Article

C2 - 21035839

AN - SCOPUS:78149359894

VL - 376

SP - 1604

EP - 1615

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9752

ER -